O’Neill, J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. The Review on Antimicrobial Resistance, http://www.his.org.uk/files/4514/1829/6668/AMR_Review_Paper_-_Tackling_a_crisis_for_the_health_and_wealth_of_nations_1.pdf (2014).
Klugman, K. P. & Black, S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc. Natl Acad. Sci. USA 115, 12896–12901 (2018).
Kennedy, D. A. & Read, A. F. Why does drug resistance readily evolve but vaccine resistance does not? Proc. Biol. Sci. 284, https://doi.org/10.1098/rspb.2016.2562 (2017).
Nichol, K. L. Influenza vaccination in the elderly: impact on hospitalisation and mortality. Drugs Aging 22, 495–515 (2005).
Poland, G. A., Jacobson, R. M. & Ovsyannikova, I. G. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine 27, 3240–3244 (2009).
Rappuoli, R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19, 2688–2691 (2001).
Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327 (2018).
Lecrenier, N. et al. Development of a recombinant adjuvanted herpes zoster subunit vaccine and its implications for shingles prevention. Expert Rev. Vaccines. 17, 619–634 (2018).
World Health Organization. Ten threats to global health in 2019. https://www.who.int/emergencies/ten-threats-to-global-health-in-2019 (2019)
Cassini, A. et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect. Dis. 19, 56–66 (2019).
Esposito, S. & De Simone, G. Update on the main MDR pathogens: prevalence and treatment options. Infez. Med 25, 301–310 (2017).
Weiner, L. M. et al. Vital signs: preventing antibiotic-resistant infections in hospitals—United States, 2014. Am. J. Transpl. 16, 2224–2230 (2016).
Centers for Disease Control and Pevention. ABCs: Surveillance Reports Main Page—Active Bacterial Core Surveillance, http://www.cdc.gov/abcs/reports-findings/surv-reports.html (2020)
Sogaard, M., Norgaard, M., Dethlefsen, C. & Schonheyder, H. C. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin. Infect. Dis. 52, 61–69 (2011).
Laupland, K. B. & Church, D. L. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin. Microbiol Rev. 27, 647–664 (2014).
Poolman, J. T. & Wacker, M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J. Infect. Dis. 213, 6–13 (2016).
Global tuberculosis report 2019. Geneva: World Health Organizatio. Licence: CC BY-NC-SA3.OIGO. https://www.who.int/tb/publications/global_report/en/. (2019)
Lessa, F. C., Winston, L. G. & McDonald, L. C., Emerging Infections Program, C. d. S. T. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 2369–2370 (2015).
Centers for Disease Control and Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morb. Mortal. Wkly Rep. 61, 157–162 (2012).
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf (2013)
Fay, K. et al. Assessment of health care exposures and outcomes in adult patients with sepsis and septic shock. JAMA Netw. Open 3, e206004 (2020).
Kyaw, M. H. et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354, 1455–1463 (2006).
Bloom, D. E., Black, S., Salisbury, D. & Rappuoli, R. Antimicrobial resistance and the role of vaccines. Proc. Natl Acad. Sci. USA 115, 12868–12871 (2018).
United Nations, Department of Economic and Social Affairs. World Population Prospects: 2019. Highlights. https://population.un.org/wpp/Publications/Files/WPP2019_10KeyFindings.pdf (2019).
Gruver, A. L., Hudson, L. L. & Sempowski, G. D. Immunosenescence of ageing. J. Pathol. 211, 144–156 (2007).
Aabenhus, R., Hansen, M. P., Siersma, V. & Bjerrum, L. Clinical indications for antibiotic use in Danish general practice: results from a nationwide electronic prescription database. Scand. J. Prim. Health Care 35, 162–169 (2017).
Murphy, S. L., Xu, J., Kochanek, K. D., Curtin, S. C. & Arias, E. Deaths: final data for 2015. Natl Vital-Stat. Rep. 66, 1–75 (2017).
Ani, C., Farshidpanah, S., Bellinghausen Stewart, A. & Nguyen, H. B. Variations in Organism-Specific Severe Sepsis Mortality in the United States: 1999-2008. Crit. Care Med. https://doi.org/10.1097/CCM.0000000000000555 (2014).
Edelsberg, J. et al. Prevalence of antibiotic resistance in US hospitals. Diagn. Microbiol Infect. Dis. 78, 255–262 (2014).
Sievert, D. M. et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34, 1–14 (2013).
Weiner, L. M. et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect. Control Hosp. Epidemiol. 37, 1288–1301 (2016).
Rhee, C. et al. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw. Open 3, e202899 (2020).
Laupland, K. B., Kibsey, P. C., Gregson, D. B. & Galbraith, J. C. Population-based laboratory assessment of the burden of community-onset bloodstream infection in Victoria, Canada. Epidemiol. Infect. 141, 174–180 (2013).
Skogberg, K., Lyytikainen, O., Ruutu, P., Ollgren, J. & Nuorti, J. P. Increase in bloodstream infections in Finland, 1995-2002. Epidemiol. Infect. 136, 108–114 (2008).
Wilson, J. et al. Trends among pathogens reported as causing bacteraemia in England, 2004–2008. Clin. Microbiol Infect. 17, 451–458 (2011).
Cunningham, A. L. et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N. Engl. J. Med. 375, 1019–1032 (2016).
HEPLISAV-B. Prescribing Information. https://www.heplisavb.com/assets/pdfs/HEPLISAV-B-Prescribing-Information.pdf (2020).
Byng-Maddick, R. & Noursadeghi, M. Does tuberculosis threaten our ageing populations? BMC Infect. Dis. 16, 119 (2016).
Urwin, R. et al. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun. 72, 5955–5962 (2004).
Nizet, V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol. 120, 13–22 (2007).
Silva Miranda, M., Breiman, A., Allain, S., Deknuydt, F. & Altare, F. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria? Clin. Dev. Immunol. 2012, 139127 (2012).
Lucero, M. G. et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst. Rev. CD004977, (2009).
Thumburu, K. K. et al. Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials. Ther. Adv. Vaccines 3, 31–40 (2015).
Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372, 1114–1125 (2015).
Huttner, A. et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(17)30108-1 (2017).
Scherpenisse, M. et al. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum. Vaccin Immunother. 9, 314–321 (2013).
Kaur, R., Kim, T., Casey, J. R. & Pichichero, M. E. Antibody in middle ear fluid of children originates predominantly from sera and nasopharyngeal secretions. Clin. Vaccin. Immunol. 19, 1593–1596 (2012).
Wagner, D. K. et al. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 25, 559–562 (1987).
DeLyria, E. S., Redline, R. W. & Blanchard, T. G. Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 136, 247–256 (2009).
Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA 111, 787–792 (2014).
Brown, A. F. et al. Memory Th1 cells are protective in invasive Staphylococcus aureus Infection. PLoS Pathog. 11, e1005226 (2015).
Middleton, D. R., Sun, L., Paschall, A. V. & Avci, F. Y. T cell-mediated humoral immune responses to type 3 capsular polysaccharide of Streptococcus pneumoniae. J. Immunol. 199, 598–603 (2017).
Guglani, L. & Khader, S. A. Th17 cytokines in mucosal immunity and inflammation. Curr. Opin. HIV AIDS 5, 120–127 (2010).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485–517 (2009).
Bao, S., Beagley, K. W., France, M. P., Shen, J. & Husband, A. J. Interferon-gamma plays a critical role in intestinal immunity against Salmonella typhimurium infection. Immunology 99, 464–472 (2000).
Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249–2254 (1993).
Reinhardt, R. L., Liang, H. E. & Locksley, R. M. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol. 10, 385–393 (2009).
Takagi, R. et al. B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J. Immunol. 181, 186–189 (2008).
Amezcua Vesely, M. C. et al. Effector TH17 cells give rise to long-lived trm cells that are essential for an immediate response against bacterial infection. Cell 178, 1176–1188 (2019). e1115.
Levy, R. et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc. Natl Acad. Sci. USA 113, E8277–E8285 (2016).
Auderset, F. et al. Reactivating immunity primed by acellular pertussis vaccines in the absence of circulating antibodies: enhanced bacterial control by TLR9 rather than TLR4 agonist-including formulation. Front Immunol. 10, 1520 (2019).
da Silva Antunes, R. et al. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. J. Clin. Invest. 128, 3853–3865 (2018).
Allen, A. C. et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. Mucosal Immunol. 11, 1763–1776 (2018).
Wilk, M. M. et al. Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis. Emerg. Microbes Infect. 8, 169–185 (2019).
Rakshit, S. et al. BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults. JCI Insight 4, https://doi.org/10.1172/jci.insight.130540 (2019).
Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 379, 138–149 (2018).
Lee, C. J. Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry. Biologicals 30, 97–103 (2002).
Lees, A., Nelson, B. L. & Mond, J. J. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14, 190–198 (1996).
Gavi The vaccine Alliance. Pneumonia vaccine saves 500,000 lives in world’s poorest countries. https://www.gavi.org/pneumonia-vaccine-saves-500000-lives-in-world-s-poorest-countries (2017).
Weinberger, D. M., Malley, R. & Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962–1973 (2011).
Bijlsma, M. W. et al. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. Lancet Infect. Dis. 14, 805–812 (2014).
Adam, H. J. et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 28, 4073–4078 (2010).
Wyres, K. L. et al. Pneumococcal capsular switching: a historical perspective. J. Infect. Dis. 207, 439–449 (2013).
Alicino, C. et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis. Vaccine 35, 5776–5785 (2017).
Ewald, H. et al. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Dtsch Arztebl Int 113, 139–146 (2016).
Denoël, P. et al. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 29, 5495–5501 (2011).
Feldman, M. F. et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc. Natl Acad. Sci. USA 102, 3016–3021 (2005).
Ihssen, J. et al. Production of glycoprotein vaccines in Escherichia coli. Microb. Cell Factories 9, 61 (2010).
Verez-Bencomo, V. et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type B. Science 305, 522–525 (2004).
Zhang, F., Lu, Y. J. & Malley, R. Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc. Natl Acad. Sci. USA 110, 13564–13569 (2013).
Sun, X., Stefanetti, G., Berti, F. & Kasper, D. L. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Proc. Natl Acad. Sci. USA 116, 193–198 (2019).
Storsaeter, J. & Wolter, J. Is there a need for a new generation of vaccines against pertussis? Expert Opin. Emerg. Drugs 11, 195–205 (2006).
Meade, B. D., Plotkin, S. A. & Locht, C. Possible options for new pertussis vaccines. J. Infect. Dis. 209(Suppl 1), S24–S27 (2014).
Ross, P. J. et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 9, e1003264 (2013).
Decker, M. D., Greenberg, D. P., Johnson, D. R. & Pool, V. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP. Vaccine, https://doi.org/10.1016/j.vaccine.2019.07.015 (2019).
Lambert, E. E., Buisman, A. M. & van Els, C. Superior B. pertussis Specific CD4+ T-Cell Immunity Imprinted by Natural Infection. Adv. Exp. Med. Biol. https://doi.org/10.1007/5584_2019_405 (2019).
Ibsen, P. H. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 14, 359–368 (1996).
Nasso, M. et al. Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms. J. Immunol. 183, 1892–1899 (2009).
Pizza, M. et al. Mutants of pertussis toxin suitable for vaccine development. Science 246, 497–500 (1989).
Seubert, A., D’Oro, U., Scarselli, M. & Pizza, M. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines. Expert Rev. Vaccines 13, 1191–1204 (2014).
Greco, D. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334, 341–348 (1996).
Guiso, N., Rocancourt, M., Szatanik, M. & Alonso, J. M. Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen. Micro. Pathog. 7, 373–380 (1989).
Guiso, N. Bordetella adenylate cyclase-hemolysin toxins. Toxins (Basel) 9, https://doi.org/10.3390/toxins9090277 (2017).
Nigrovic, L. E. & Thompson, K. M. The Lyme vaccine: a cautionary tale. Epidemiol. Infect. 135, 1–8 (2007).
Plotkin, S. A. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin. Infect. Dis. 52(Suppl 3), s271–s275 (2011).
Poolman, J. T. & Richmond, P. Multivalent Meningococcal Serogroup B vaccines: challenges in predicting protection and measuring effectiveness. Expert Rev. Vaccines. 14, 1277–1287 (2015).
Ladhani, S. N. et al. Vaccination of Infants with Meningococcal Group B vaccine (4CMenB) in England. N. Engl. J. Med. 382, 309–317 (2020).
Tait, D. R. et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 381, 2429–2439 (2019).
Lai, R., Afkhami, S., Haddadi, S., Jeyanathan, M. & Xing, Z. Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments. Eur. Respir. Rev. 24, 356–360 (2015).
Li, M. et al. Mucosal vaccines: strategies and challenges. Immunol. Lett. 217, 116–125 (2020).
Redi, D., Raffaelli, C. S., Rossetti, B., De Luca, A. & Montagnani, F. Staphylococcus aureus vaccine preclinical and clinical development: current state of the art. N. Microbiol. 41, 208–213 (2018).
RTT News Dec 21 2018. Pfizer Discontinues Phase 2b STRIVE Clinical Trial Due To Futility [cited 2019 Feb 28]. https://markets.businessinsider.com/news/stocks/pfizer-discontinues-phase-2b-strive-clinical-trial-due-to-futility-1027827494.
Guerra, F. E., Borgogna, T. R., Patel, D. M., Sward, E. W. & Voyich, J. M. Epic immune battles of history: neutrophils vs. Staphylococcus aureus. Front Cell Infect. Microbiol 7, 286 (2017).
Fowler, V. G. et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309, 1368–1378 (2013).
Fattom, A. et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum. Vaccin Immunother. 11, 632–641 (2015).
Broker, B. M., Mrochen, D. & Peton, V. The T cell response to Staphylococcus aureus. Pathogens 5, https://doi.org/10.3390/pathogens5010031 (2016).
Miller, L. S., Fowler, V. G., Shukla, S. K., Rose, W. E. & Proctor, R. A. Development of a vaccine against Staphylococcus aureus invasive infections: evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiol. Rev. 44, 123–153 (2020).
Ramos-Sevillano, E., Ercoli, G. & Brown, J. S. Mechanisms of naturally acquired immunity to Streptococcus pneumoniae. Front Immunol. 10, 358 (2019).
Garde, D. Genocea halts its antibiotic vaccine program after a Phase II failure. FierceBiotech https://www.fiercebiotech.com/r-d/genocea-halts-its-antibiotic-vaccine-program-after-a-phase-ii-failure (2015).
Odutola, A. et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study. Vaccine 35, 2531–2542 (2017).
Delahaye, J. L. et al. Cutting edge: bacillus calmette-guerin-induced t cells shape mycobacterium tuberculosis infection before reducing the bacterial burden. J. Immunol. https://doi.org/10.4049/jimmunol.1900108 (2019).
Joosten, S. A. et al. Mycobacterial growth inhibition is associated with trained innate immunity. J. Clin. Invest. 128, 1837–1851 (2018).
Covian, C. et al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front Immunol. 10, 2806 (2019).
Fine, P. E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet (London, England) 346, 1339–1345 (1995).
Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173–1180 (2006).
Tubo, N. J. & Jenkins, M. K. CD4+ T cells: guardians of the phagosome. Clin. Microbiol. Rev. 27, 200–213 (2014).
Andersen, P. & Scriba, T. J. Moving tuberculosis vaccines from theory to practice. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-019-0174-z (2019).
Rodo, M. J. et al. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog. 15, e1007643 (2019).
Sheehan, S. et al. A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults. PLoS ONE 10, e0141687 (2015).
Van Der Meeren, O. et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 379, 1621–1634 (2018).
Suliman, S. et al. Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. a double-blind, placebo-controlled, dose-selection trial. Am. J. Respir. Crit. Care Med 199, 220–231 (2019).
Schrager, L. K., Harris, R. C. & Vekemans, J. Research and development of new tuberculosis vaccines: a review. F1000Res. 7, 1732 (2018).
Hansen, S. G. et al. Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nat. Med. 24, 130–143 (2018).
Griffiths, K. L., Villarreal, D. O., Weiner, D. B. & Khader, S. A. A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis. Hum. Vaccin Immunother. 12, 2649–2653 (2016).
Hoelzer, K. et al. Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet. Res. 49, 70 (2018).
Williamson, D. A., Lim, A., Wiles, S., Roberts, S. A. & Freeman, J. T. Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005-2011. BMC Infect. Dis. 13, 385 (2013).
Turnidge, J. D. et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med. J. Aust. 191, 368–373 (2009).
Jain, S. et al. Community-acquired pneumonia requiring hospitalization among U.S. Adults. N. Engl. J. Med. 373, 415–427 (2015).
Prymula, R. et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367, 740–748 (2006).
Kilpi, T. et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37, 1155–1164 (2003).
Eskola, J. et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344, 403–409 (2001).
Black, S. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187–195 (2000).
Valeri, M. & Raffatellu, M. Cytokines IL-17 and IL-22 in the host response to infection. Pathog. Dis. 74, https://doi.org/10.1093/femspd/ftw111 (2016).
Kuwabara, T., Ishikawa, F., Kondo, M. & Kakiuchi, T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017, 3908061 (2017).